A ​decade on, the German ⁠pharma giant is ​worth less than ​the $62 bln it paid for Roundup's maker. ​Known legal risks ...

Bayer used illegal and anti-competitive practices to monopolize the U.S. market for ​genetically engineered corn seeds, reaping "hundreds of millions, if not billions, of ill-gotten dollars," ...

Bayer BAYN0.55%increase; green up pointing triangle said it agreed to buy Perfuse Therapeutics for up to $2.45 billion, snapping up an eye-drug specialist that is developing a potential glaucoma ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US biotech Perfuse Therapeutic and its novel drug implant for eye diseases. The deal ...

While pesticides are making us sick, corporations like Bayer are seeking immunity from lawsuits over harms linked to their products. Their efforts are failing. While pesticides are making us sick, ...

The German company Bayer has faced extensive scrutiny and legal action over the herbicide Roundup and allegations that it causes cancer, since acquiring the product's maker, Monsanto, in 2018. Now, ...

The Supreme Court grilled Bayer over whether it is liable for failing to warn consumers that its flagship weedkiller Roundup might cause cancer, in a case that could wipe out thousands of legal claims ...

Washington – The U.S. Supreme Court was hearing arguments on Monday in Bayer AG's effort to shut down thousands of lawsuits accusing the company of failing to warn users that the active ingredient in ...

The US Supreme Court gave Bayer AG a mixed reception on its bid to stop tens of thousands of lawsuits claiming its Roundup herbicide should have been labeled as a cancer risk. Hearing arguments in ...

This is the first in a three-part series on Bayer’s crusade for immunity from Roundup-related cancer claims, published in partnership with the Center for Media and Democracy. Read the second and third ...

A bill preventing states and local governments from issuing warnings about the risks of pesticides is on track to pass the House. In the eight years since it bought Monsanto—along with the liability ...